Generation Bio (NASDAQ:GBIO – Get Rating) posted its earnings results on Thursday. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.03), Fidelity Earnings reports.
Generation Bio Stock Up 0.4 %
Shares of NASDAQ GBIO traded up $0.03 during trading on Friday, hitting $8.08. The company had a trading volume of 922,807 shares, compared to its average volume of 358,834. The stock has a 50 day simple moving average of $6.53 and a 200 day simple moving average of $6.27. Generation Bio has a 12 month low of $3.96 and a 12 month high of $28.67.
Wall Street Analyst Weigh In
GBIO has been the topic of a number of recent research reports. Needham & Company LLC lowered their target price on Generation Bio from $27.00 to $23.00 and set a “buy” rating on the stock in a report on Friday. Wedbush reissued an “outperform” rating and issued a $24.00 target price on shares of Generation Bio in a report on Friday. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Generation Bio presently has an average rating of “Moderate Buy” and a consensus price target of $19.00.
Institutional Inflows and Outflows
Generation Bio Company Profile
Generation Bio Co, a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology.
- Get a free copy of the StockNews.com research report on Generation Bio (GBIO)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for Generation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generation Bio and related companies with MarketBeat.com's FREE daily email newsletter.